ArticleFrontiers in pediatrics2025
Antibiotic optimization in hospitalized children with non-severe community-acquired pneumonia: lessons from an antimicrobial stewardship intervention (2022-2024).
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Community-acquired pneumonia (CAP) is a leading cause of hospitalization and antibiotic use in children. Despite guidelines recommending narrow-spectrum regimens and shorter treatment durations, prescribing practices remain inconsistent. This study assessed the impact of a newly implemented diagnostic and therapeutic clinical pathway (CP) as part of an antimicrobial stewardship (AMS) intervention in a tertiary care pediatric hospital. Methods: A single-center, retrospective observational study was conducted on children aged 28 days to 18 years hospitalized with non-severe, uncomplicated CAP from January 2022 to December 2024. The CP was implemented on January 1st, 2024. Antibiotic prescribing patterns, clinical outcomes, and predictors of short-course therapy (≤5 days) were compared between pre- and post-CP periods. Multivariate logistic regression identified predictors of intravenous (IV) therapy ≤48 h, total therapy ≤5 days, and ampicillin use as first-line agent. Results: The study included 263 CAP episodes in 250 children. Following the implementation of CP, the use of ampicillin as a first-line IV antibiotic significantly increased [19/99 (19%) vs. 1/164 (0.6%); Conclusions: CP implementation improved adherence to evidence-based antibiotic prescribing, reduced broad-spectrum use, and increased early IV-to-oral transitions without compromising outcomes. However, unchanged therapy duration and LOS highlight the need for further AMS interventions, clinician education, and integration of viral and bacterial diagnostics to support optimal antibiotic use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.